Records
Every government record, registry entry, journal paper and filing we have checked, in one list. Filter by peptide or type. Each row says what the record says, what we could not confirm, and the day we opened it.
161 records. Filters need JavaScript.
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. State-licensed pharmacies, federal facilities and licensed physicians would not face enforcement for compounding the listed peptides, under conditions including a patient-specific prescription and quality testing. Not FDA approval. HHS says it may revisit the policy if a safety or quality problem arises.
Caveat: Draft and nonbinding. Six peptides covered; this record applies to each of them.
Verified Oct 31, 2026
- Public comment docket HHS-OASH-2026-0496
Status: Comments open until Nov 14, 2026. Docket for the HHS draft enforcement policy on compounded peptides.
Caveat: Not re-opened in the latest check (automated access blocked). The dossier links it without a summary.
Verified Oct 31, 2026
- Public comment docket HHS-OASH-2026-0496
Status: Comments open until Nov 14, 2026. Docket for the HHS draft enforcement policy on compounded peptides.
Caveat: Not re-opened in the latest check (automated access blocked).
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. State-licensed pharmacies, federal facilities and licensed physicians would not face enforcement for compounding the listed peptides, under conditions including a patient-specific prescription and quality testing. Not FDA approval.
Caveat: The notice does not itself name the peptides; coverage of this peptide rests on a law-firm summary.
Verified Oct 31, 2026
- Public comment docket HHS-OASH-2026-0496
Status: Comments open until Nov 14, 2026. Docket for the HHS draft enforcement policy on compounded peptides.
Caveat: Not re-opened in the latest check (automated access blocked).
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. PEG-MGF is not one of the six peptides the policy covers, per two law-firm summaries.
Caveat: The notice does not itself name the peptides; that this peptide is outside the policy rests on law-firm summaries.
Verified Oct 31, 2026
- Public comment docket HHS-OASH-2026-0496
Status: Comments open until Nov 14, 2026. Docket for the HHS draft enforcement policy on compounded peptides.
Caveat: Not re-opened in the latest check (automated access blocked).
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. State-licensed pharmacies, federal facilities and licensed physicians would not face enforcement for compounding the listed peptides, under conditions including a patient-specific prescription and quality testing. Not FDA approval.
Caveat: The notice does not itself name the peptides; coverage of this peptide rests on a law-firm summary.
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. Melanotan II is not one of the six peptides the policy covers, per two law-firm summaries.
Caveat: The notice does not itself name the peptides; that this peptide is outside the policy rests on law-firm summaries.
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. Emideltide is not one of the six peptides the policy covers, per two law-firm summaries.
Caveat: The notice does not itself name the peptides; that this peptide is outside the policy rests on law-firm summaries.
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. Dihexa is not one of the six peptides the policy covers, per two law-firm summaries.
Caveat: The notice does not itself name the peptides; that this peptide is outside the policy rests on law-firm summaries.
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. LL-37 is not one of the six peptides the policy covers, per two law-firm summaries.
Caveat: The notice does not itself name the peptides; that this peptide is outside the policy rests on law-firm summaries.
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. GHK-Cu is not one of the six peptides the policy covers, per two law-firm summaries.
Caveat: The notice does not itself name the peptides; that this peptide is outside the policy rests on law-firm summaries.
Verified Oct 31, 2026
- Public comment docket HHS-OASH-2026-0496
Status: Comments open until Nov 14, 2026. Docket for the HHS draft enforcement policy on compounded peptides.
Caveat: Not re-opened in the latest check (automated access blocked). The dossier links it without a summary.
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. State-licensed pharmacies, federal facilities and licensed physicians would not face enforcement for compounding the listed peptides, under conditions including a patient-specific prescription and quality testing. Not FDA approval. HHS says it may revisit the policy if a safety or quality problem arises.
Caveat: Draft and nonbinding. Six peptides covered; this record applies to each of them.
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. State-licensed pharmacies, federal facilities and licensed physicians would not face enforcement for compounding the listed peptides, under conditions including a patient-specific prescription and quality testing. Not FDA approval.
Caveat: The notice does not itself name the peptides; coverage of this peptide rests on a law-firm summary.
Verified Oct 31, 2026
- Public comment docket HHS-OASH-2026-0496
Status: Comments open until Nov 14, 2026. Docket for the HHS draft enforcement policy on compounded peptides.
Caveat: Not re-opened in the latest check (automated access blocked).
Verified Oct 31, 2026
- HHS draft policy pausing enforcement on six compounded peptides (Federal Register)
Status: Draft policy; comments open until Nov 14, 2026. State-licensed pharmacies, federal facilities and licensed physicians would not face enforcement for compounding the listed peptides, under conditions including a patient-specific prescription and quality testing. Not FDA approval.
Caveat: The notice does not itself name the peptides; coverage of this peptide rests on a law-firm summary.
Verified Oct 31, 2026
- Investigational Peptides in Orthopaedic Practice: BPC-157, Thymosin Beta-4 and TB-500
Status: Online ahead of print. Narrative review (Tham, Hodgkins and Kennedy, J Am Acad Orthop Surg) searching through June 2026. Finds human musculoskeletal evidence limited to one small retrospective uncontrolled case series and no validated dosing, pharmacokinetic or long-term safety data. Concludes routine clinical use cannot currently be recommended.
Verified Oct 31, 2026
- Investigational Peptides in Orthopaedic Practice: BPC-157, Thymosin Beta-4 and TB-500
Status: Online ahead of print. Narrative review of BPC-157, thymosin beta-4 and TB-500, searched through June 2026. Calls TB-500 a distinct seven-amino-acid fragment often conflated with full-length thymosin beta-4. Finds no FDA-approved musculoskeletal indication, product quality concerns, and concludes routine clinical use cannot currently be recommended.
Caveat: Abstract read; full text not read.
Verified Oct 31, 2026
- Early Phase 1 topical anti-aging peptide serum study, one of five peptides (Frontiers in Bioscience Research Institute and Aging)
Status: Enrolling by invitation. Planned 48 participants, one site in Irvine, California. Estimated start Oct 21, 2026. No results posted.
Caveat: Epitalon is one of five peptides in a topical serum; not an injection study.
Verified Oct 31, 2026
- Early Phase 1 study with a topical serum of five peptides including GHK-Cu (Frontiers in Bioscience Research Institute in Aging and Cancer)
Status: Enrolling by invitation. Planned 48 participants, one site in Irvine, California. Estimated start Oct 21, 2026. No results posted.
Caveat: GHK-Cu is one of five peptides in a topical serum; not an injection study.
Verified Oct 31, 2026
- Epitalon and Epithalamin: A Narrative Review (Int J Mol Sci)
Status: Published. Human evidence limited to small studies; no adequately powered randomized trial.
Caveat: Review.
Verified Oct 31, 2026
- Narrative review of BPC-157 for liver protection (Sever et al., Pharmaceuticals)
Status: Published. Summarizes animal-model findings, including on portal hypertension. The authors state that experimental evidence, however extensive, does not establish clinical efficacy.
Caveat: Author list includes Predrag Sikiric and Sven Seiwerth, who also wrote several other recent BPC-157 papers in PubMed.
Verified Oct 31, 2026
- BPC-157 pilot after rotator cuff repair (University of Arkansas)
Status: Not yet recruiting. Summary says 20 patients, enrollment field says 30.
Verified Oct 31, 2026
- A beverage with anti-fatigue and mood-regulating functions and its preparation method
Status: Published application, not granted. Applicant 南京医科大学. Filed Jul 15, 2026.
Caveat: Title as listed by Google Patents (machine translation). Legal status and claims not checked.
Verified Oct 31, 2026
- Polypeptide, polypeptide variant, preparation method, composition and application thereof
Status: Published application, not granted. Applicant 诺为泰(昆明)生物科技有限公司. Filed May 25, 2026.
Caveat: Title as listed by Google Patents (machine translation). Legal status and claims not checked; the link to BPC-157 is from the Google Patents text match.
Verified Oct 31, 2026
- Fifty 1 Labs Reg A offering (part II and III)
Status: Filed. Describes itself as a biotechnology company focused on peptide products, naming BPC-157 and TB-500.
Caveat: A company statement about its own business, not a finding about the peptide.
Verified Oct 31, 2026
- Fifty 1 Labs Reg A offering (part II and III)
Status: Filed. Biotechnology company focused on peptide products, naming BPC-157 and TB-500.
Verified Oct 31, 2026
- Open-label BPC-157 supplement gummy study (Parlay Wellness)
Status: Completed. 40 participants, 8 weeks, no control group, registered after it ended.
Verified Oct 31, 2026
- Holland & Knight: FDA advisory committee endorses compounding of certain peptides
Status: Published. Says the committee did not recommend emideltide and recommended the other six peptides it reviewed. Gives no vote counts.
Caveat: Law-firm summary, secondary source. Publication day not confirmed; August 2026.
Verified Oct 31, 2026
- Public Citizen testimony to the Pharmacy Compounding Advisory Committee about BPC-157
Status: Testimony. Argues the benefit evidence is mostly anecdotal, no trials support the proposed routes, the mechanism is unclear, and impurities could raise immune risks.
Caveat: Advocacy group testimony, not a finding. Automated access was blocked in the latest check; the summary comes from the dossier earlier read.
Verified Oct 31, 2026
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats
Status: Published. 32 rats after Achilles tendon repair, 4 weeks. TB-500 group had higher load to failure and better tendon scores than controls; the BPC-157 and TB-500 combination added no benefit over either alone. Authors call it exploratory.
Caveat: Abstract read; full text, funding and disclosures not read.
Verified Oct 31, 2026
- X39 patch and circulating GHK and GHK-Cu levels in healthy adults (LifeWave)
Status: Not yet recruiting. Tests a patch, not GHK-Cu itself. Planned 100 participants, one site in London, Canada. Estimated start Jan 2027.
Caveat: Registry entry is sponsor-written.
Verified Oct 31, 2026
- Sublingual semaglutide-BPC 157 combination for weight loss
Status: Published application, not granted. Applicant Red Mountain Med Spa, LLC. Priority May 15, 2023, filed Feb 20, 2026.
Caveat: Legal status not checked. Claims not read.
Verified Oct 31, 2026
- Systematic review of GHK-Cu in topical microneedle delivery (Arch Intern Med Res)
Status: Published. Says the human literature is thin and fragmented, with most randomized trials small and on facial cosmetic creams.
Caveat: Review; abstract only; journal not assessed. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Spinnaker ETF Series 485APOS
Status: Filed. Risk language noting the July 23-24 FDA committee meeting would evaluate BPC-157 among other peptides.
Caveat: A company statement about its own business, not a finding about the peptide.
Verified Oct 31, 2026
- Application of gastric pentadecapeptide in the preparation of drugs for treating immune checkpoint inhibitor-associated colitis
Status: Published application, not granted. Applicant 陕西医药控股医药研究院有限公司. Filed Apr 30, 2026.
Caveat: Title as listed by Google Patents (machine translation). Legal status and claims not checked.
Verified Oct 31, 2026
- Apparatus and method for peptide stack determination
Status: Published. Applicant: Ageless Medicine Systems. Priority Dec 10, 2024.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- BPC-157 sodium salt oral dissolving film formulation for treating acute alcohol poisoning and its preparation method
Status: Published application, not granted. Applicant 杭州昊肽生物科技有限公司. Filed Feb 6, 2026.
Caveat: Title as listed by Google Patents (machine translation). Legal status and claims not checked.
Verified Oct 31, 2026
- Preprint: GHK-Cu in middle-aged mice, intraperitoneal or intranasal (Res Sq)
Status: Published. Mouse study.
Caveat: Preprint, not peer reviewed; abstract only.
Verified Oct 31, 2026
- FDA briefing document for July 2026 advisory committee: TB-500 (free base and acetate)
Status: Proposed not to add to 503A list. No human data found. No repeat-dose, genotoxicity or carcinogenicity studies. Poorly characterized. Immunogenicity risk.
Verified Oct 31, 2026
- FDA briefing document for July 2026 advisory committee: Epitalon (free base and acetate)
Status: Proposed not to add to 503A list. No clinical safety data in humans. Effectiveness for insomnia not shown. Telomerase and cancer-risk concern. No FAERS reports.
Verified Oct 31, 2026
- FDA briefing document for July 2026 advisory committee: KPV (free base and acetate)
Status: Proposed not to add to 503A list. No human data. 8 nonclinical articles submitted. Not well characterized. No FAERS reports.
Verified Oct 31, 2026
- FDA briefing document for July 2026 advisory committee: Emideltide (free base and acetate)
Status: Proposed not to add to 503A list. Balance of criteria weighs against listing. Not well characterized; effectiveness evidence insufficient; no clinical safety data for the proposed subcutaneous route. No FAERS reports through Mar 3, 2024.
Verified Oct 31, 2026
- BioScience Health Innovations 10-Q listing "Melanotan II - Skin pigmentation"
Status: Filed. Lists Melanotan II among 14 peptides the company expects to return to Category 1, citing a Feb 27, 2026 statement by the HHS Secretary. Says reclassification is not FDA approval.
Caveat: Company claim, not a finding. Read the passages naming the peptide only.
Verified Oct 31, 2026
- FDA staff briefing for the committee on BPC-157
Status: Criteria weighed against listing. Only UC use evaluated; sparse human data; animal clotting and liver signals.
Verified Oct 31, 2026
- FDA briefing document for July 2026 advisory committee: MOTS-c (free base and acetate)
Status: Proposed not to add to 503A list. No clinical or human exposure data. Cell and rodent models only. Not well characterized. No FAERS reports.
Verified Oct 31, 2026
- BioScience Health Innovations 10-Q listing "PEG-MGF - Muscle repair"
Status: Filed. Lists PEG-MGF among 14 peptides the company expects to return to Category 1, citing a Feb 27, 2026 statement by the HHS Secretary. Says reclassification is not FDA approval.
Caveat: Company claim, not a finding. Read the passages naming the peptide only.
Verified Oct 31, 2026
- BioScience Health Innovations 10-Q listing GHK-Cu
Status: Filed. Lists GHK-Cu among 14 peptides the company expects to return to Category 1, citing a Feb 27, 2026 statement by the HHS Secretary. Says reclassification is not FDA approval.
Caveat: Company claim, not a finding. Read the passages naming the peptide only.
Verified Oct 31, 2026
- BioScience Health Innovations 10-Q
Status: Filed. Filed May 11, 2026, listed alongside the 10-K on the dossier. Its contents were not summarized separately.
Caveat: Contents not separately read. A company statement about its own business, not a finding about the peptide.
Verified Oct 31, 2026
- BioScience Health Innovations 10-Q listing "DSIP (Emideltide)"
Status: Filed. Lists emideltide among 14 peptides the company expects to return to Category 1, citing a Feb 27, 2026 statement by the HHS Secretary. Says reclassification is not FDA approval.
Caveat: Company claim, not a finding. Read the passages naming the peptide only.
Verified Oct 31, 2026
- FDA briefing document for July 2026 advisory committee: Semax (free base and acetate)
Status: Proposed not to add to 503A list. No human pharmacokinetic data. Effectiveness evidence insufficient. One FAERS consumer report (eye pain after nasal drops).
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (Emideltide)
Status: Listed (nominated but withdrawn). FDA has not identified safety-related information for the proposed route of administration.
Caveat: Content current Apr 22, 2026 per the page.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (Dihexa)
Status: Listed (nominated but withdrawn)
Caveat: Content current Apr 22, 2026 per the page.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (GHK-Cu)
Status: Listed (nominated but withdrawn)
Caveat: Content current Apr 22, 2026 per the page.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (LL-37)
Status: Listed (nominated but withdrawn)
Caveat: Content current Apr 22, 2026 per the page.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (Melanotan II)
Status: Listed (nominated but withdrawn)
Caveat: Content current Apr 22, 2026 per the page.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (KPV)
Status: Listed. No human exposure data identified by FDA for any route. Content current Apr 22, 2026.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (MOTS-c)
Status: Listed. Immunogenicity risk for certain routes; peptide-related impurity and characterization concerns. No human exposure data identified. Content current Apr 22, 2026.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (BPC-157)
Status: Listed. Says compounded drugs containing BPC-157 may pose immunogenicity risk for certain routes and have peptide-impurity and ingredient-characterization problems. FDA found no or only limited safety information for the proposed routes. Content current Apr 22, 2026.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (Semax)
Status: Listed. Immunogenicity risk for certain routes; no, or limited, safety information for proposed routes. Content current Apr 22, 2026.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (PEG-MGF)
Status: Listed (nominated but withdrawn)
Caveat: Content current Apr 22, 2026 per the page.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (Epitalon)
Status: Listed (nominated but withdrawn). Listed under substances nominated but withdrawn. FDA has not identified safety-related information for the proposed route. Content current Apr 22, 2026.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (thymosin beta-4 fragment LKKTETQ, TB-500)
Status: Listed. Immunogenicity risk for certain routes; no human exposure data identified. Content current Apr 22, 2026.
Verified Oct 31, 2026
- FDA notice of July 2026 advisory committee meeting on seven peptides
Status: Published. Dihexa is not among the substances the notice lists.
Caveat: Read directly.
Verified Oct 31, 2026
- FDA notice of July 2026 advisory committee meeting on seven peptides
Status: Published. LL-37 is not among the substances the notice lists.
Caveat: Read directly.
Verified Oct 31, 2026
- FDA notice of July 2026 advisory committee meeting on seven peptides
Status: Published. PEG-MGF is not among the substances the notice lists.
Caveat: Read directly.
Verified Oct 31, 2026
- FDA notice of July 2026 advisory committee meeting naming emideltide
Status: Published. Lists emideltide with opioid withdrawal, chronic insomnia and narcolepsy as evaluated uses.
Caveat: Read directly.
Verified Oct 31, 2026
- FDA notice of July 2026 advisory committee meeting on seven peptides
Status: Published. GHK-Cu is not among the substances the notice lists.
Caveat: Read directly.
Verified Oct 31, 2026
- FDA notice of July 2026 advisory committee meeting on seven peptides
Status: Published. Melanotan II is not among the substances the notice lists.
Caveat: Read directly.
Verified Oct 31, 2026
- Simultaneous analysis of food-borne doping substances using liquid ... (a testing method; title shortened)
Status: Published application. Applicant: Korea Institute of Science and Technology. Priority Oct 7, 2024.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- Phase 2a placebo-controlled MOTS-c study in prediabetes with overweight/obesity (Hudson Biotech)
Status: Recruiting. Planned 120 participants, 12 weeks subcutaneous MOTS-c vs placebo, one site in Shenzhen. Estimated primary completion Feb 2027. No results posted.
Caveat: Same sponsor as a TB-500 record whose summary calls itself fictional; this record does not contain that wording. Unverified.
Verified Oct 31, 2026
- BioScience Health Innovations 10-K
Status: Filed. Says its oral delivery system could unlock commercial pathways for formulations containing BPC-157 if FDA formally enacts a reclassification of peptides that the company describes as announced Feb 27, 2026. Lists BPC-157 among peptides it aims to deliver orally.
Caveat: A company statement about its own business, not a finding about the peptide.
Verified Oct 31, 2026
- Phase 1/2 placebo-controlled TB-500 study in stable ASCVD (Hudson Biotech)
Status: Recruiting. Planned 80 participants, three dose cohorts, one site in Shenzhen. Estimated primary completion Feb 2027. No results posted.
Caveat: Record summary says: This fictional study is an example of a ClinicalTrials.gov-style record. Unverified.
Verified Oct 31, 2026
- A Paradise Acquisition Corp. Rule 425 (merger partner Enhanced Ltd.) naming GHK-Cu
Status: Filed. A shareholder email lists GHK-Cu among "already allowed peptides" the partner plans to launch.
Caveat: Company claim, not a finding. What "already allowed" refers to is not stated.
Verified Oct 31, 2026
- A Paradise Acquisition Corp. Rule 425 (merger partner Enhanced Ltd.)
Status: Filed. A shareholder email from its merger partner, Enhanced Ltd., lists BPC-157 among peptides it intends to provide if the regulatory change occurs.
Caveat: A company statement about its own business, not a finding about the peptide.
Verified Oct 31, 2026
- Phase 2 Melanotan II adjunct to NB-UVB phototherapy in vitiligo (Hudson Biotech)
Status: Recruiting. Planned 60 participants, one site, Peking University Shenzhen Hospital. Started Feb 2, 2026. Dose and route given only as "per protocol". No results posted.
Caveat: Summary begins "This example interventional study record describes". Same sponsor, site and start date as the BPC-157, TB-500, MOTS-c and GHK-Cu records. Cannot be independently confirmed.
Verified Oct 31, 2026
- Phase 2 topical GHK-Cu gel for acute skin wound healing (Hudson Biotech)
Status: Recruiting. Planned 60 participants, one site, Peking University Shenzhen Hospital. Started Feb 2, 2026. No results posted.
Caveat: Same sponsor, site and start date as the BPC-157, TB-500, MOTS-c and Melanotan II records; the TB-500 record calls itself a fictional example. Cannot be independently confirmed.
Verified Oct 31, 2026
- Phase 2 placebo-controlled BPC-157 in acute hamstring strain (Hudson Biotech)
Status: Recruiting. Planned 120 participants, Shenzhen, started Feb 2, 2026.
Verified Oct 31, 2026
- Synergistic combination of NAD+ and therapeutic peptides delivered via ... (title shortened by Google Patents)
Status: Published application. Applicant: Nicholas Jerome Andrews. Priority Apr 22, 2024. Second US application in the same family of titles.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- Systemic MOTS-c levels are increased in adults with obesity (J Clin Transl Endocrinol)
Status: Published. 32 obese vs 22 lean adults; 10 followed after bariatric surgery. Measured levels only.
Verified Oct 31, 2026
- WADA 2022 and 2026 Prohibited Lists: Semax not named
Status: Not named
Caveat: Only the 2022 and 2026 editions were checked. Section S0 covers substances with no government approval.
Verified Oct 31, 2026
- WADA 2026 Prohibited List, S4.4.1: mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)
Status: Prohibited
Caveat: 2022 and 2026 editions checked; 2022 does not name it.
Verified Oct 31, 2026
- WADA 2022 and 2026 Prohibited Lists: KPV not named
Status: Not named
Caveat: Only the 2022 and 2026 editions were checked. Section S0 covers substances with no government approval.
Verified Oct 31, 2026
- WADA 2022 and 2026 Prohibited Lists: emideltide and DSIP not named
Status: Not named
Caveat: Only the 2022 and 2026 editions were checked. Section S0 covers substances with no government approval.
Verified Oct 31, 2026
- WADA 2022 and 2026 Prohibited Lists: GHK-Cu not named
Status: Not named
Caveat: Only the 2022 and 2026 editions were checked. Section S0 covers substances with no government approval.
Verified Oct 31, 2026
- WADA 2022 and 2026 Prohibited Lists: LL-37 not named
Status: Not named
Caveat: Only the 2022 and 2026 editions were checked. Section S0 covers substances with no government approval.
Verified Oct 31, 2026
- WADA 2022 and 2026 Prohibited Lists: Dihexa not named
Status: Not named
Caveat: Only the 2022 and 2026 editions were checked. The 2026 list names hepatocyte growth factor in S2.3; whether S2.3 reaches dihexa is not stated by WADA in anything we read.
Verified Oct 31, 2026
- WADA 2022 and 2026 Prohibited Lists: mechano growth factors (MGFs) named; PEG-MGF not named
Status: MGFs named as a class
Caveat: Only the 2022 and 2026 editions were checked. We found no WADA text naming PEG-MGF or addressing pegylated forms.
Verified Oct 31, 2026
- WADA 2022 and 2026 Prohibited Lists: Melanotan II not named
Status: Not named
Caveat: Only the 2022 and 2026 editions were checked. Section S0 covers substances with no government approval.
Verified Oct 31, 2026
- WADA 2022 and 2026 Prohibited Lists: Epitalon not named
Status: Not named
Caveat: Only the 2022 and 2026 editions were checked. Section S0 covers substances with no government approval.
Verified Oct 31, 2026
- Review of performance-enhancing peptides modulating the GH-IGF1 axis (Front Endocrinol (Lausanne))
Status: Published. Lists PEG-MGF among IGF-1 analogues marketed as research compounds; adverse effects reported for the group.
Caveat: Review; effects not specific to PEG-MGF; abstract only. PubMed gives no day or month, so the date shown is approximate.
Verified Oct 31, 2026
- Carnyx Therapeutics Form C offering statement naming epitalon
Status: Filed. Company says its sleep program is a peptide analog of epitalon, and that epitalon is off-patent.
Caveat: Company claim, not a finding. Filing day not shown in the document; December 2025.
Verified Oct 31, 2026
- Synergistic combination of NAD+ and therapeutic peptides delivered via ... (title shortened by Google Patents)
Status: Published application. Applicant: Nicholas Jerome Andrews. Priority Apr 22, 2024. Matched TB-500 with thymosin.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- Regenerative Medical Technology Group 10-Q (BPC-157 and TB-500 pen)
Status: Filed. Describes a preloaded BPC-157 and TB-500 injectable pen as its current best seller.
Caveat: A company statement about its own business, not a finding about the peptide.
Verified Oct 31, 2026
- Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma? (Int J Oral Maxillofac Surg)
Status: Published. Case report posing the question.
Caveat: Case report; title only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Regenerative Medical Technology Group 10-Q (BPC-157 and TB-500 pen)
Status: Filed. Describes a preloaded BPC-157 and TB-500 injectable pen as its current best seller.
Caveat: A company statement about its own business, not a finding about the peptide.
Verified Oct 31, 2026
- Regenerative Medical Technology Group 10-Q (BPC-157 and TB-500 pen)
Status: Filed. Describes a BPC-157 and TB-500 injectable pen as current best seller.
Verified Oct 31, 2026
- Systematic review of BPC-157 in orthopaedic sports medicine (Vasireddi et al., HSS Journal)
Status: Published. Of 36 articles, 35 were preclinical and 1 was clinical. Authors conclude it shows promise in animal models, that human safety is unknown, and urge caution. Animal safety data covered six weeks or less.
Verified Oct 31, 2026
- Composition for tissue regeneration and wound healing containing thymosin beta- ... (title shortened by Google Patents)
Status: Published application. Applicant: Korea Institute of Science and Technology. Priority Dec 19, 2023.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- Retraction notice for the 2014 dihexa mechanism paper (J Pharmacol Exp Ther)
Status: Published. Notice of retraction of PMID 25187433.
Caveat: PubMed record shows no stated reason; notice not read. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Application of TB500 in the preparation of drugs for preventing or treating ... (title shortened by Google Patents)
Status: Published application. Applicant: Guangdong Ocean University. Priority Aug 30, 2023.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- Quantification of TB-500 and its metabolites in vitro and in rats (UHPLC-Orbitrap MS/MS)
Status: Published. Analytical method paper with in-vitro wound-healing screening.
Caveat: Abstract read. Full text, funding and disclosures not read. Dated from PubMed (issue date Mar 1, 2024, online Feb 7, 2024).
Verified Oct 31, 2026
- Athira Pharma Form 10-K (fiscal 2023): special committee findings and the dihexa patent
Status: Filed. Company says its special committee found altered images in a former executive's dissertation and at least four papers published 2011-2014, and that the licensed dihexa patent incorporated some.
Caveat: Company statement, not a finding by an authority. Individuals not named here. Passages only.
Verified Oct 31, 2026
- Randomized trial of LL-37 cream in diabetic foot ulcers (Arch Dermatol Res)
Status: Published. Greater increase in granulation index with LL-37 on days 7 to 28.
Caveat: Abstract only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Randomized trial of recombinant Lactococcus lactis "Oral LL-37" in COVID-19, 238 inpatients (J Med Virol)
Status: Published. Authors report shorter time to negative viral test with early treatment and no severe adverse events.
Caveat: Product is a recombinant bacterium preparation, not the peptide. Abstract only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Warning letter to Warrior Labz naming TB-500 and BPC-157
Status: Issued. Online seller offering TB-500 and BPC-157 alongside SARMs.
Caveat: Found by web search; list may be incomplete.
Verified Oct 31, 2026
- Warning letter to Warrior Labz (online seller)
Status: Issued. Its website took orders for BPC-157 (injectable and nasal spray) and TB-500, alongside SARMs and other products. Issued by FDA drug center.
Caveat: Found by web search and opened; list of letters may be incomplete. A letter states FDA position at the time, not a court finding.
Verified Oct 31, 2026
- WADA 2022 Prohibited List, S2: Thymosin-beta4 and its derivatives e.g. TB-500
Status: Prohibited
Caveat: Only the 2022 edition was checked.
Verified Oct 31, 2026
- WADA 2022 Prohibited List, S0: names BPC-157 as an example of non-approved substances
Status: Prohibited. The 2022 list says the non-approved substances class covers many substances including but not limited to BPC-157. S0 already covered any substance without government approval for human therapeutic use, so the 2022 text names it as an example.
Caveat: Only the 2021 and 2022 editions were checked.
Verified Oct 31, 2026
- Dihexa in APP/PS1 mice (Brain Sci)
Status: Published. Reports restored spatial learning and reduced inflammatory markers in mice.
Caveat: Animal study; abstract only.
Verified Oct 31, 2026
- Warning letter to Advanced Nutriceuticals (Guyer Institute), compounder
Status: Issued. Lists BPC-157 among substances that were not nominated for the 503A bulks list.
Caveat: Found by web search and opened; list of letters may be incomplete. A letter states FDA position at the time, not a court finding.
Verified Oct 31, 2026
- Phase IIb venous leg ulcer trial of topical LL-37, 148 patients (Wound Repair Regen)
Status: Published. No significant overall improvement in healing; post hoc improvement in wounds of at least 10 cm2; well tolerated per authors.
Caveat: Abstract only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Athira Pharma Form 8-K: ATH-1017 metabolizes into dihexa; dihexa development discontinued
Status: Filed. Company says its candidate is a prodrug that metabolizes into dihexa, a WSU compound it licensed, and that it discontinued dihexa development after 2015.
Caveat: Company claim, not a finding. Athira is now LeonaBio, Inc.
Verified Oct 31, 2026
- Notice of concern on the 2013 dihexa design paper (J Pharmacol Exp Ther)
Status: Published. Notice of concern on PMID 23055539.
Caveat: Notice not read. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Notice of concern on the 2014 dihexa mechanism paper (J Pharmacol Exp Ther)
Status: Published. Notice of concern on PMID 25187433.
Caveat: Notice not read. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans (J Appl Physiol)
Status: Published. Randomized exercise study, 30 volunteers; measured levels, not an injection.
Verified Oct 31, 2026
- DSIP and motor function in rats after focal stroke (Molecules)
Status: Published. Animal study, per title.
Caveat: Animal study; title only.
Verified Oct 31, 2026
- Melanotan tanning injection: a rare cause of priapism (Sex Med)
Status: Published. Case report.
Caveat: Case report; title only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Warning letter to Predator Nutrition (supplement seller)
Status: Issued. A product labeled to contain BPC-157 was among those FDA said were marketed with claims to mitigate, prevent or treat disease. Issued by FDA food center.
Caveat: Found by web search and opened; list of letters may be incomplete. A letter states FDA position at the time, not a court finding.
Verified Oct 31, 2026
- Warning letter to Tailor Made Compounding LLC naming Semax among 22 substances
Status: Issued. Compounding pharmacy inspection. FDA says drugs made from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: Found by web search and read directly. List of letters may be incomplete. A warning letter is about the firm, not a finding about the substance.
Verified Oct 31, 2026
- Warning letter to Tailor Made Compounding LLC naming Epitalon among 22 substances
Status: Issued. Compounding pharmacy inspection. FDA says drugs made from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: Found by web search and read directly. List of letters may be incomplete. A warning letter is about the firm, not a finding about the substance.
Verified Oct 31, 2026
- Warning letter to Tailor Made Compounding LLC naming DSIP among 22 substances
Status: Issued. Compounding pharmacy inspection. FDA says drugs made from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: Found by web search and read directly. List of letters may be incomplete. A warning letter is about the firm, not a finding about the substance.
Verified Oct 31, 2026
- Warning letter to Tailor Made Compounding LLC naming LL-37 among 22 substances
Status: Issued. Compounding pharmacy inspection. FDA says drugs made from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: Found by web search and read directly. List of letters may be incomplete. A warning letter is about the firm, not a finding about the substance.
Verified Oct 31, 2026
- Warning letter to Tailor Made Compounding (compounding pharmacy)
Status: Issued. Investigators noted the pharmacy compounded products using BPC 157, among many other peptides.
Caveat: Found by web search and opened; list of letters may be incomplete. A letter states FDA position at the time, not a court finding.
Verified Oct 31, 2026
- Warning letter to Tailor Made Compounding LLC naming GHK-Cu among 22 substances
Status: Issued. Compounding pharmacy inspection. FDA says drugs made from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: Found by web search and read directly. List of letters may be incomplete. A warning letter is about the firm, not a finding about the substance.
Verified Oct 31, 2026
- Warning letter to Tailor Made Compounding LLC naming Melanotan II among 22 substances
Status: Issued. Compounding pharmacy inspection. FDA says drugs made from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: Found by web search and read directly. List of letters may be incomplete. A warning letter is about the firm, not a finding about the substance.
Verified Oct 31, 2026
- Warning letter to Tailor Made Compounding LLC naming PEG-MGF among 22 substances
Status: Issued. Compounding pharmacy inspection. FDA says drugs made from the listed bulk substances were not eligible for the 503A exemptions.
Caveat: Found by web search and read directly. List of letters may be incomplete. A warning letter is about the firm, not a finding about the substance.
Verified Oct 31, 2026
- The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations (Drug Test Anal)
Status: Published. Semax found in seized preparations; authors say it has not completed clinical trials.
Verified Oct 31, 2026
- Phase 2 LL-37 cream on diabetic foot ulcers (Universitas Indonesia)
Status: Status unknown. Planned 40 participants. No results posted.
Caveat: Registry entry is sponsor-written. Start date is estimated and given only as Oct 2019.
Verified Oct 31, 2026
- Warning letter to PD Labs (compounding pharmacy)
Status: Issued. Cites compounding with BPC-157 acetate, notes it was not nominated for the 503A bulks list, and records the firm saying it would continue to compound it.
Caveat: Found by web search and opened; list of letters may be incomplete. A letter states FDA position at the time, not a court finding.
Verified Oct 31, 2026
- Melanotan-induced priapism: a hard-earned tan (BMJ Case Rep)
Status: Published. Case report with review.
Caveat: Case report; title only.
Verified Oct 31, 2026
- The efficacy of semax in the treatment of patients at different stages of ischemic stroke (Zh Nevrol Psikhiatr)
Status: Published. 110 patients; BDNF and recovery measures.
Caveat: Russian journal; English abstract only.
Verified Oct 31, 2026
- Detection and in vitro metabolism of confiscated BPC 157 and MGF R23H (Drug Test Anal)
Status: Published. Detection study of a variant found in confiscated vials.
Caveat: Detection study, not a study of PEG-MGF; abstract only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- FDA debarment order after a federal conviction connected to sale of Melanotan II (81 FR 79501)
Status: Issued. Permanent debarment of the owner of a company that sold Melanotan II, after a 2015 conviction on two conspiracy counts. Describes Melanotan II as an unapproved new drug marketed as an injectable tanning product.
Caveat: Individual not named here. A debarment order is about a person, not a finding about the substance.
Verified Oct 31, 2026
- Phase 1 oral BPC-157 tablets in healthy volunteers (PharmaCotherapia)
Status: Status unknown. Planned 42 volunteers in Tijuana; last verified Oct 2015; no results.
Caveat: Month of posting approximate.
Verified Oct 31, 2026
- Phase 1/2 intratumoral injections of LL37 for melanoma (M.D. Anderson Cancer Center)
Status: Completed. Four participants, starting dose 250 micrograms per tumor weekly for up to 8 weeks. Results posted.
Caveat: Registry entry is sponsor-written. Date shown is the study start date.
Verified Oct 31, 2026
- Dihexa and the HGF/c-Met system (J Pharmacol Exp Ther)
Status: Published. Reports dihexa binds HGF and that its effects depend on HGF/c-Met.
Caveat: RETRACTED (notice Apr 2025); notice of concern Sep 2021. Reason not read. Abstract only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Melanoma associated with the use of melanotan-II (Dermatology)
Status: Published. Case of melanoma in a 20-year-old woman who injected it and used sunbeds.
Caveat: Case report; temporal association, not proof of cause. Abstract only. PubMed gives no day or month, so the date shown is approximate.
Verified Oct 31, 2026
- Melanotan and the posterior reversible encephalopathy syndrome (Ann Intern Med)
Status: Published. Case report letter.
Caveat: Case report; no abstract in PubMed.
Verified Oct 31, 2026
- Design of dihexa from angiotensin IV analogs (J Pharmacol Exp Ther)
Status: Published. Reports an orally active, blood-brain-barrier-permeant analog with antidementia-type effects in lab tests.
Caveat: Carries a Sep 2021 notice of concern; abstract only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Melanotan II injection resulting in systemic toxicity and rhabdomyolysis (Clin Toxicol (Phila))
Status: Published. Case report.
Caveat: Case report; title only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Amidated MGF analogues identified in black-market products (Rapid Commun Mass Spectrom)
Status: Published. Mass spectrometry of two black-market preparations.
Caveat: Detection study, not a study of PEG-MGF; abstract only.
Verified Oct 31, 2026
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease (Inflamm Bowel Dis)
Status: Published. Mouse colitis models.
Caveat: Animal study.
Verified Oct 31, 2026
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (Gastroenterology)
Status: Published. Lab and cell transporter study.
Caveat: Not a human study.
Verified Oct 31, 2026
- Randomized trial of GHK-Cu skin care after CO2 laser resurfacing (Arch Facial Plast Surg)
Status: Published. 13 patients completed it. No significant difference in erythema; questionnaire favored GHK-Cu for overall skin quality (P = .04).
Caveat: Small trial; abstract only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa (Neuro Endocrinol Lett)
Status: Published. Abstract reports a 90% positive effect; no group sizes given.
Caveat: Small study from one research group; abstract only.
Verified Oct 31, 2026
- BPC peptide salts with organo-protective activity, the process for their preparation and their use in therapy
Status: Granted US patent (current legal status not checked). Original BPC filing family. Priority May 23, 1997, filed May 20, 1998. Inventor Predrag Sikiric, who also authors many of the BPC-157 papers in PubMed. The family was filed in more than 20 jurisdictions.
Caveat: A 1998 filing would normally expire about 20 years after filing; each family member was not checked. A patent shows what an owner claims, not that a product works or is safe.
Verified Oct 31, 2026
- Melanotan II in men with organic erectile dysfunction (Urology)
Status: Published. 4 of 19 injections associated with severe nausea.
Caveat: Small crossover study; abstract only.
Verified Oct 31, 2026
- Melanotan-II in men with psychogenic erectile dysfunction (J Urol)
Status: Published. Erections in 8 of 10 men; nausea, stretching, yawning more frequent than placebo.
Caveat: Small crossover study; abstract only. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Open clinical trial of DSIP in opioid detoxification (J Clin Psychopharmacol)
Status: Published. Title read only.
Caveat: Letter; title only, no abstract read. PubMed gives no day, so the date shown is approximate.
Verified Oct 31, 2026
- Effectiveness of semax in acute period of hemispheric ischemic stroke (Zh Nevrol Psikhiatr)
Status: Published. 30 Semax patients vs 80 controls.
Caveat: Russian journal; English abstract only.
Verified Oct 31, 2026
- Phase I pilot study of melanotan-II in 3 healthy men (Life Sci)
Status: Published. Somnolence, nausea, spontaneous erections and increased pigmentation reported.
Caveat: Very small; abstract only. PubMed gives no day or month, so the date shown is approximate.
Verified Oct 31, 2026
- Double-blind study of DSIP in 16 chronic insomniacs (Neuropsychobiology)
Status: Published. Authors say effects were weak and short-term treatment is not likely to be of major benefit.
Caveat: Small; abstract only. PubMed gives no day or month, so the date shown is approximate.
Verified Oct 31, 2026
- Placebo-controlled study of DSIP in 14 chronic insomniacs (Eur Neurol)
Status: Published. Authors report improved night sleep and daytime performance over 7 nights.
Caveat: Small, 1987; abstract only. PubMed gives no day or month, so the date shown is approximate.
Verified Oct 31, 2026
- DSIP in the treatment of withdrawal syndromes from alcohol and opiates (Eur Neurol)
Status: Published. Title read only.
Caveat: Title only, no abstract read. PubMed gives no day or month, so the date shown is approximate.
Verified Oct 31, 2026
- Holland & Knight: FDA advisory committee endorses compounding of certain peptides
Status: Law firm summary. Reports the July 23-24 committee recommended BPC-157 for the compounding list, with emideltide the exception among the peptides reviewed. The vote is nonbinding.
Caveat: Secondary source. Vote tallies were not available in the sources read. Automated access was blocked in the latest check; the summary comes from the dossier earlier read.
Verified Oct 31, 2026
- WADA 2021 Prohibited List (does not name BPC-157)
Status: Not named. The 2021 list does not name BPC-157.
Caveat: Included for comparison with 2022.
Verified Oct 31, 2026
- Interstitial cystitis pilot study (Lee, Walker and Ayadi, Altern Ther Health Med)
Status: Published Oct 2024. 12 women whose previous drug had failed got a single 10 mg injection around the bladder lesion during a cystoscopy. All reported symptom relief on a questionnaire; no adverse events were reported.
Caveat: No control group. Compounding pharmacy product used. Same first author and journal as the 2025 IV report. Full text not read.
Verified Oct 31, 2026
- Intravenous safety pilot in two adults (Lee and Burgess, Altern Ther Health Med)
Status: Published Sept 2025. Two adults received up to 20 mg by infusion. No change in the tested blood markers and no side effects reported. Authors call for further studies.
Caveat: Two participants, no placebo. Both had received intravenous BPC-157 before. The abstract does not say where the BPC-157 came from. Full text not read.
Verified Oct 31, 2026
Records are added when we verify them against the primary source. A record here is not an endorsement of what it says. Missing items are listed on each dossier under “Still not covered.”